

For personal use only

WELLNEXLIFE

Next Generation Consumer Health Products

Wellnex Life Limited ASX: WNX

August 2024

Important Notice & Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND (SAVE AS SET OUT BELOW) ARE NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES")), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING IS UNLAWFUL OR TO ANY RESIDENT THEREOF. THIS PRESENTATION IS NOT AN OFFER OR AN INVITATION TO BUY OR SELL SECURITIES.

The information contained in this Presentation contains confidential information relating to Wellnex Life Limited (the **Company**) and has been prepared by the Company. This Presentation, and any ancillary documents relating to it, including any oral presentation and any question or answer session (together, the **Materials**) have been prepared and issued by and are the sole responsibility of the Company. By reading the information contained in the Materials and this notice, the recipient agrees to be bound by the following limitations.

The Materials are being made available for your information only and are delivered by the Company in connection with the potential admission of the issued and to be issued share capital (the **Shares**) of the Company on the Main Market of the London Stock Exchange (the **Admission**). The presentation slides are given in conjunction with an oral presentation and should not be taken out of context.

The Materials are confidential and must not be recorded, copied, distributed, reproduced, stored in a retrieval system, transmitted or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm) or published in whole or in part, for any purpose or under any circumstances at any time, without the prior written consent of each of the Company and Strand Hanson Limited (**Strand**) and Orana Capital LLP (**Orana**) (together, the **Joint Brokers**). Save as set out below, the information in the Materials is exclusively intended for persons who are not in the United States, Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction in which it is unlawful to provide such access. The Materials are neither directed at, nor intended for access or use by, any person or entity that is a citizen or resident or physically located in any locality, state or country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration, qualification by prospectus or licensing within such jurisdiction.

Viewing and receiving the information in the Materials may not be lawful in certain jurisdictions. Also, in some jurisdictions only certain categories of persons may be allowed to access the Materials. Any persons who wish to access the Materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The Materials are for information purposes only and are not an offer or an invitation to buy or sell securities in the United States or elsewhere. The Materials are not for use in the United States and may not be retransmitted, published, released or redistributed in or into the United States by any recipient hereof.

The Shares have not been and will not be registered under the US Securities Act, or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in or into the United States absent registration under the US Securities Act, or in a transaction that is exempt from, or otherwise not subject to, the registration requirements of the US Securities Act and in accordance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offering of the Shares in the United States, the United Kingdom or elsewhere.

Any person who wishes to access the Materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and that the Company is not otherwise prohibited from providing the Materials to that person in that jurisdiction. If any such prohibition applies, or you are in any doubt as to whether any such prohibition applies, please do not access the Materials. It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements.

Neither receipt of the Materials by any person, nor any information contained in them, supplied with them or subsequently communicated to any person by, or on behalf of, the Company, the Joint Brokers or any of their respective affiliates or by any of their respective directors, officers, employees, members, agents, advisers, representatives or shareholders (collectively, **Representatives**), either constitutes or is to be taken as constituting the giving of investment advice by the Company, the Joint Brokers or any of their respective affiliates or any of their respective Representatives to any person. Each recipient of the Materials should make its own independent assessment of the merits or otherwise of the Materials and the Admission and should take its own independent legal, investment, tax and other professional advice. The Materials are not intended to form (and should not therefore be relied upon as forming) the basis of any investment, financing or other decision. The Materials do not purport to be comprehensive or to contain all the information that may be relevant to recipients relating to the Company or the Admission. Each recipient of the Materials must make its own investigation and assessment of the Company and the Admission.

The contents of the Materials have not been examined or approved by the Financial Conduct Authority (the **FCA**), London Stock Exchange plc or any other regulatory body, nor is it intended that the Materials will be so examined or approved. The information and opinions presented or contained in the Materials are subject to verification, updating, completion, correction, revision and amendment in any way without liability or notice to any person. None of the Company, the Joint Brokers or any of their respective affiliates or any of their respective Representatives undertakes any obligation to verify, update, complete, correct, revise or amend the Materials or to provide recipients with access to any additional information that may arise in connection with it. Prospective investors are advised to conduct their own due diligence.

Important Notice & Disclaimer

Strand and Orana are authorised and regulated in the United Kingdom by the FCA and are acting exclusively for the Company and for no one else in connection with the Admission and will not regard any other person (whether or not a recipient of the Materials) as a client in relation to the Admission or any transaction, arrangement or other matter referred to in the Materials and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for giving advice in relation to the Admission or any transaction, arrangement or other matter referred to in the Materials.

No representation, warranty, undertaking or other assurance, express or implied, is or will be made or given and no responsibility or liability is or will be accepted by the Company, the Joint Brokers (apart from any responsibilities or liabilities that may be imposed by FSMA, or the regulatory regime established thereunder) or any of their respective affiliates or any of their respective Representatives in relation to the adequacy, accuracy, fairness or completeness of the information and opinions contained in, or the use of, the Materials, or as to any such information or opinions remaining unchanged after the Materials are issued (and no-one is authorised to do so on behalf of any of them). The Company, the Joint Brokers, their respective affiliates and their respective Representatives expressly disclaim, to the maximum extent permitted by law, any responsibility or liability, whether express or implied, arising in tort, contract or otherwise, for the Materials and any information and opinions contained therein, and for any errors, omissions or misstatements contained in the Materials.

Certain statements contained in the Materials contain (or may contain) certain forward-looking statements with respect to the Company's current expectations, beliefs, intentions, estimates and projections about future events, strategic initiatives and the Company's future financial condition and performance. These statements sometimes use words such as "aim", "believes", "estimates", "may", "will", "should", "plans", "anticipates", "could", "potential", "expects", "anticipates", "plans", "intends", "projects", "indicates" and words or terms of similar meaning (or the negative thereof). By their nature, forward-looking statements are inherently predictive, speculative and involve risks, uncertainties and assumptions that could cause actual results, financial condition, performance, developments or achievements to differ materially from those expressed or implied by the forward-looking statements. Many of these risks, uncertainties and assumptions relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. These forward-looking statements speak only as of the date of the relevant Materials. Undue reliance should not be placed on these forward-looking statements. In particular, but without prejudice to the generality of the above, no representation or warranty is given, and no responsibility or liability is accepted, either as to the achievement or reasonableness of any future projections, forecasts, estimates or statements as to any prospects or future returns contained or referred to in the Materials or in relation to the basis or assumptions underlying such projections, forecasts, estimates or statements. Except as required by applicable law or regulation, each of the Company and the Joint Brokers expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements whether as a result of new information, future events or otherwise.

The Company has included non-IFRS financial measures in the Materials. These measurements may not be comparable to those of other companies. Reference to these non-IFRS financial measures should be considered in addition to IFRS financial measures, but should not be considered a substitute for results that are presented in accordance with IFRS.

No statement in the Materials is or is intended to be a profit forecast or profit estimate or to imply that the earnings of the Company for the current or future financial periods will necessarily match or exceed the historical or published earnings of the Company and/or its subsidiaries. No statement of a financial metric should be interpreted to mean that any financial metric for the current or future financial years would necessarily match or exceed the historical published position of the Company and/or its subsidiaries. The estimates set out in the Materials have been prepared based on numerous assumptions and forecasts, including those set out in the Materials, some of which are outside of the Company's influence and/or control, and are therefore inherently uncertain. The estimates have not been audited, reviewed, verified or subject to any procedures by the Company's auditors. You should not place undue reliance on them and there can be no guarantee or assurance that they will be correct.

Certain figures contained in the Materials may have been subject to rounding adjustments. Accordingly, the actual arithmetic total of numbers may not conform exactly to the total figures and percentages may not conform exactly to percentages that would be derived if calculations were based on rounded numbers.

The price of the Shares and any income from them may go down as well as up and investors may not get back the full amount invested on disposal of such Shares. None of the Company, the Joint Brokers, any of their respective affiliates, or any of their respective Representatives, shall be liable for any direct, indirect or consequential loss or damage (including, without limitation, loss of profit) suffered by any person as a result of relying on any statement or omission in any information contained in the Materials or any future communication, written or oral, in connection with the Materials or the Admission.

Important Notice & Disclaimer

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the **UK Product Governance Requirements**), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process, which has determined that the Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each defined in paragraph 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all permitted distribution channels (the **Target Market Assessment**). Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the UK Product Governance Requirements) should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Admission.

Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Brokers will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

By attending the Presentation or by otherwise accessing the Materials, you warrant, represent, undertake and acknowledge to each of the Company and the Joint Brokers that: (a) you have read, understood and agree to comply with the foregoing limitations and restrictions including, without limitation, the obligation to keep strictly confidential the information contained in the Materials or made available in connection with further enquiries to the extent such information is not made publicly available (otherwise than through a breach by you of this provision); (b) you are able to receive the Materials without contravention of any applicable legal or regulatory restrictions; (c) if you are in Australia, the Materials have been provided to you on the basis that you have confirmed your representation to the Company that you are either: (i) a "sophisticated investor" within the meaning of section 708(8) of the Australian Corporations Act 2001 and, if applicable, you have provided an accountant's certificate in accordance with section 708(8)(c)(i) or (ii) of the Australian Corporations Act 2001 and related regulations to the Company before receiving the Materials; (ii) a "professional investor" within the meaning of section 708(11) of the Australian Corporations Act 2001; or (iii) a person associated with Constance under section 708(12) of the Australian Corporations Act 2001; (d) if you are in the European Economic Area, you are a Qualified Investor; (e) if you are in the United Kingdom, you are a "relevant person"; (f) you are either (i) a "qualified institutional buyer" as defined in Rule 144A under the US Securities Act or (ii) located outside of the United States; (g) you will not at any time have any discussion, correspondence or contact concerning the information in the Materials with any of the Representatives of the Company nor with any of its suppliers, nor any governmental or regulatory body, without the prior written consent of the Company; and (h) you will not deal in (or encourage any other person to deal in) the Shares or financial instruments of the Company or base any behaviour on any inside information you receive as part of the Materials until you have ceased to have such inside information.

Certain information contained in the Materials may constitute inside information for the purposes of the Criminal Justice Act 1993 and the EU Market Abuse Regulation (2014/596/EU) (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended) (**UK MAR**). You agree and accept that you will not deal or encourage any other person to deal in the securities of the Company whilst you remain in possession of such inside information (i.e. until the transaction and other inside information described in the Materials is announced or until the Company or the Joint Brokers have confirmed to you that you are no longer in possession of inside information) and will not engage in behaviour which would amount to market abuse. Dealing in securities of the Company when in possession of inside information could result in liability under the insider dealing restrictions set out in the Criminal Justice Act 1993 or UK MAR. The Materials may contain information which is not generally available, but which, if available, would or would be likely to be regarded as relevant when deciding the terms on which transactions in the shares of the Company should be effected. Unreasonable behaviour based on such information could result in liability under the market abuse or insider dealing provisions of UK MAR or under other applicable laws and/or regulations in other jurisdictions.

The information contained in the Materials and any further information made available by, or on behalf of, the Company or the Joint Brokers relating to the Company or any of its subsidiaries or subsidiary undertakings will not form the basis of any contract, does not constitute or form part of, and should not be construed as, an offer, invitation, inducement, solicitation or recommendation for the taking of any action, the acquisition of any asset of, or securities in, the Company or any other entity or the making of any investment, commercial or financial decisions and does not otherwise constitute an agreement to provide investment services. The Materials or any part thereof, or the fact of their distribution, shall not form the basis of, or be relied upon in connection with, any contract or commitment by or with Singers or the Company, or their respective affiliates or Representatives, for any purpose.

These Materials are not, and should not be construed as, a prospectus and no prospectus or offering document will be made available in any jurisdiction in connection with the matters contained or referred to in the Materials or the Admission and no such prospectus is required to be published, in accordance with the Financial Services and Markets Act 2000, as amended (**FSMA**) or Regulation (EU) 2017/1129 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended).

Wellnex Life Team

Decades of Experience in Healthcare & FMCG



Zack Bozinovski
Managing Director

- Over 35 years of senior experience within FMCG and Pharmaceutical companies in Australia and internationally
- Held senior positions at PepsiCo, Nestlé (Uncle Tobys) and Sigma Pharmaceuticals.
- Successfully developed established and owned brands, including Voöst Vitamins, (sold to Proctor & Gamble in April 2021)



George Karafotias
Chief Executive Officer

- Specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success
- Established track record with publicly-traded businesses, predominantly in senior executive positions.
- Accounting & Finance tertiary education.

Vivienne Zhang
GM Finance

- A seasoned and highly efficient financial professional renowned for their meticulous attention to detail and proven expertise in finance management.

Dominique Ries
GM Marketing

- Highly experienced FMCG & Consumer Healthcare having worked with major brands under Unilever, Treasury Wines, and Ego Pharmaceuticals.

Nicholas Krogh
GM Sales

- Over 20 years experience in FMCG working with major brands including L'Oréal, Nestle Health Sciences, and Tommee Tippee.

Chris Kominatos
GM Scientific & Regulatory Affairs

- Over 20 years experience in pharmaceutical product development and obtaining TGA approvals.

Wellnex Life Non-Executive Directors

Diverse Skills Matrix to Deliver Guidance on Behalf of Stakeholders



Andrew Vidler – Non-Executive Director

- Over 30 years experience across retail, consumer health products and retail pharmacy.
- Currently Pacific Smiles Group's (PSQ:ASX) Managing Director and Chief Executive Officer.
- For the last four years Mr. Vidler worked for API Limited (now Wesfarmers Health) where he was responsible for the Priceline retail and Priceline pharmacy businesses.



Jeffrey Yeh – Non-Executive Director

- Over 21 years' experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management.
- Co-founder of Homart Pharmaceuticals (Homart) in 2002 and has grown it into a premier and award-winning manufacturing and brand business with over 200 employees and Asian market presence.
- Homart, and its related entities, currently have a 18.3% shareholding in WNX.



Eric Jiang – Non-Executive Director

- Corporate adviser and independent board member.
- Distinctive understanding of the cultural, economic and strategic context in which Australian businesses engage with Asia.
- Previously sat on the boards of ASX listed corporates Connexion Media Limited (ASX:CXZ), Perpetual Resources Limited (ASX:PEC) and Wingara AG Limited (ASX:WNR).

Investment Highlights

WNL is an ASX-listed consumer health company with a diversified portfolio of unique products, brands, and IP licensed to global blue-chip customers.



Transformational Margins & Profitability



Initiation of Global Distribution of Proven Brands



Expansion of Haleon Licensing Deal



Chemist Warehouse JV in Medicinal Cannabis



Wellnex Life Asset Portfolio

WELLNEXLIFE



Transformation of Wellnex Life


For personal use only




Wellnex Life Profitability Evolution

Successful transition from low-margin brokerage to high-margin brand sales


For personal use only



Jan - June 2023



Jan - June 2024




Gross Profit H2 FY24

Brand Growth & Expanding Margins

WNX's portfolio of 100% owned brands are high gross margin products that are growing Company profitability rapidly.


- First WNX brands launched in FY22.
- Approx. 126% CAGR revenue growth between FY22 and FY24
- Approx. 191% CAGR gross profit growth between FY22 and FY24
- Approx. 65.8% expansion in gross profit margin between FY22 and FY24
- Management expectations for continued growth in revenue and margins across WNX brands in FY25 as brand awareness continues to build.



Global Expansion of Licensing Deal

Growing our Contract Manufacturing revenue through global expansion with Haleon

- First dossier approved in FY22 followed by first major contract with Arrotex.
- TGA changes to paracetamol pack sizes disrupted revenues in FY24.
- Haleon contract extension to UK and UAE launched in FY25.
- First purchase orders from global expansion with Haleon occurred in July 2024.
- WNX update to the market signalled total licensing sales in the month of July 2024 totalling \$4.03m.



Wellness Life Medicinal Cannabis

A joint venture between Chemist Warehouse, OneLife Botanicals, & Wellnex Life




For personal use only

Australian Medicinal Cannabis Market Growth

Huge Opportunity in an Emerging Alternative Medicine Market

- In 2016, the Australian Government legalised access to medicinal cannabis.
- Since legalisation, the market has grown at an approximate CAGR of 37% to a 2023 market size of circa A\$477m with ~96.4k patients.
- Research forecasts growth to A\$548m and 102.4k patients in 2024.
- Forecasters expect the market to reach A\$710m in 2029 representing a ~5.3% CAGR from 2024.



Source: <https://www.statista.com/outlook/hmo/cannabis/medical-cannabis/australia#users>

Wellnex Life FY25 Domestic Growth Strategy

Brand building organic growth and opportunistic acquisitions



Wellnex Life International Growth Strategy

Leveraging domestic success into an international growth strategy



Pain Away is Australia's largest natural topical pain relief product. Wellnex Life are seizing on an opportunity to export the brand globally. First international sales to Chemist Warehouse NZ occurred in May 2024.



Haleon global contract expansion starting with UAE and UK. First orders placed Q1 FY25 for liquid gel caps across their pain relief brands.



An Asian distribution agreement has been signed with Homart Pharmaceuticals to market Wellnex Life brands into high growth Asian markets.



Wellnex Life UK Dual Listing



Benefits of listing on the London Stock Exchange & Selected European Public Comparables

1 Underpins European Expansion

2 Deeper Capital Pool

3 Higher Valuation Trading Multiples

4 Greater Stock Liquidity



Wellnex Life Corporate Structure

Trading on the ASX under the ticker WNX

Capital Structure

WNX Shares on Issue	1,401,882,652
WNX Options on Issue ¹	333,276,394
Fully Diluted Shares on Issue	1,735,159,046
Fully Diluted Equity Value ²	\$39,908,658

1. Options issued at various strike prices and maturities
 2. At \$0.023 per share as of close on 16 August 2024

Director Shareholdings

George Karafotias	3,838,059
Zack Bozinovski	26,642,857
Eric Jiang	2,127,609
Andrew Vidler	892,858
Jeffery Yeh	194,402,855

WNX ASX Chart



Thank You

**FOR FURTHER INFORMATION
CONTACT THE FOLLOWING:**

George Karafotias
Chief Executive Officer
george.k@wellnexlife.com.au

Zack Bozinovski
Managing Director
zack.b@wellnexlife.com.au

Wellnex Life Limited
ABN 77 150 759 363
Suite 68, Building 2, Level 3,
574 Plummer Street, Port
Melbourne VIC 3207, Australia
www.wellnexlife.com.au
Email: info@wellnexlife.com.au
Phone: +61 3 8399 9419

WELLNEXLIFE

For personal use only

Appendix

WELLNEXLIFE

Wellnex Life 100% Owned Brands

Innovative and Unique Market Leading Brands



Pain Away

Australia's second largest¹ topical pain relief brand with a range pain relief products specifically formulated for joints and topical pain

ACQUIRED: DEC 23

GROSS MARGIN: 70-75%

Wakey Wakey

Australia's first Complimentary Medicine Caffeine & Guarana Effervescent boosting energy levels.

LAUNCHED: OCT 21+ JAN 23

GROSS MARGIN: 40-50%

Nighty Night

Australia's first Complimentary Medicine Ashwagandha Effervescent helping you fall asleep faster.

LAUNCHED: JAN 2023

GROSS MARGIN: 40-50%

The Iron Company

Australia's first Complimentary Medicine Iron gummy with Slow-Release Technology for the relief of tiredness & fatigue

LAUNCHED: OCT 2021

GROSS MARGIN: 30-40%

Mr. Bright

Unique natural teeth whitening products without harmful hydrogen peroxide that whitens teeth up to 8 times whiter

ACQUIRED: DEC 2022

GROSS MARGIN: 40-50%

Wellnex Life Intellectual Property

Formulating and Launching TGA Complimentary and Registered Medicines

Pharmaceutical Dossier

- A comprehensive set of documents submitted to the Therapeutics Goods Administration (TGA) supporting product efficacy and performance
- Includes Good Manufacturing Process (GMP), development information, and necessary clinical studies
- Utilised Dossier to generate Marketing Authorisations (MA) ... our ability to clone our dossier to partners for domestic and international launches

Product Development

- Strong R&D spend over FY22 & FY23
- Identify category needs and opportunities
- Retailer Collaboration
- GMP and Quality considerations
- Manufacturing Capability and Capacity

INTELLECTUAL PROPERTY

Wellnex Life Dossier Portfolio

- Paracetamol liquid soft gel capsules
- Paracetamol & Ibuprofen liquid soft gel capsules
- Ibuprofen mini liquid soft gel capsules
- Paracetamol & caffeine liquid soft gel capsules
- Up to 5 other liquid soft gel capsule products being developed as part of our portfolio

Consumer Health Brands

- Diversified portfolio of brands for the Health and Pharmaceutical market
- Brands are still young and currently only sold in Australia
- Growth opportunities in domestic market and through international launches